Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of toripalimab combined with
anlotinib and SBRT for non-driver gene mutation untreated brain metastases non-small Cell
Lung Cancer.